- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02118597
An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients
18. oktober 2016 oppdatert av: Hoffmann-La Roche
Non-interventional Study to Observe Triple Combination Therapy With Boceprevir or Simeprevir Plus Peginterferon Alfa-2a Plus Ribavirin for Re-treatment of Chronic Hepatitis C in Hungary (IMPERIAL)
This prospective, national, multicenter, non-interventional study examined the use of triple combination therapy with boceprevir, pegylated interferon (peginterferon) alfa-2a and ribavirin in re-treating participants with genotype 1 chronic hepatitis C (CHC) infection.
Dosing and treatment duration were at the discretion of the investigator in accordance with local clinical practice and local labeling.
Participants were to be observed for the duration of their triple combination therapy and for up to 24 weeks thereafter.
Studieoversikt
Status
Avsluttet
Forhold
Studietype
Observasjonsmessig
Registrering (Faktiske)
19
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Budapest, Ungarn, 1125
-
Budapest, Ungarn, 1097
-
Békéscsaba, Ungarn, 5600
-
Debrecen, Ungarn, 4032
-
Eger, Ungarn, 3300
-
Kaposvár, Ungarn, 7400
-
Szombathely, Ungarn, 8800
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Prøvetakingsmetode
Ikke-sannsynlighetsprøve
Studiepopulasjon
Participants with genotype 1 chronic hepatitis C (CHC) infection taking triple combination therapy (boceprevir, peginterferon alfa-2a and ribavirin)
Beskrivelse
Inclusion Criteria:
- 18 years of age or over
- Genotype 1 CHC infection
- Prior unsuccessful treatment with peginterferon alfa plus ribavirin (null-response, partial response and relapsed participants)
- Receiving triple combination therapy with boceprevir, peginterferon alfa-2a and ribavirin according to standard of care and in line with local labeling
- Enrollment in the study no later than 4 weeks after start of triple combination therapy (including peginterferon alfa-2a and ribavirin lead-in phase)
Exclusion Criteria:
- Naïve participants not responding to peginterferon alfa plus ribavirin at week 4 (HCV RNA drop < 1 log10) or at week 12 (HCV RNA >/= 15 international units/milliliter [IU/mL]) and switching to triple combination therapy with boceprevir
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
Intervensjon / Behandling |
|---|---|
|
Triple Combination Therapy
Participants who demonstrated genotype 1 chronic hepatitis C infection and had a history of unsuccessful treatment with pegylated interferon (peginterferon) alfa + ribavirin, and who were subjected to receive a triple combination therapy with simeprevir or boceprevir plus peginterferon alfa-2a and ribavirin were observed.
|
Boceprevir administered according to corresponding summary of product characteristics (SmPC).
Andre navn:
Simeprevir administered according to corresponding summary of product characteristics (SmPC).
Andre navn:
Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
Andre navn:
Ribavirin according to corresponding summary of product characteristics (SmPC).
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Sustained Virological Response 24 (SVR24) Rate
Tidsramme: 24 weeks after end of treatment (EOT) at Week 72
|
The SVR 24 rate is defined as percentage of participants with Hepatitis C virus (HCV) Ribonucleic Acid (RNA) less than 15 international unit/milliliter (IU/mL) after the 24-weeks follow-up.
|
24 weeks after end of treatment (EOT) at Week 72
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants With Virological Response
Tidsramme: Weeks 4, 8, 12, and 24
|
Virological response is defined as HCV RNA <15 IU/mL.
|
Weeks 4, 8, 12, and 24
|
|
Number of Participants With Virological Breakthrough
Tidsramme: Up to Week 48
|
Virological breakthrough is defined as either HCV RNA >=15 IU/mL in participants with prior virological response or as an increase in HCV RNA >/=1 log10 above nadir.
|
Up to Week 48
|
|
Number of Participants With Virological Relapse
Tidsramme: Week 49 up to Week 72
|
Virological response is defined as HCV RNA >/=15 IU/mL during the treatment free follow-up period in participants with virological response at the end of treatment.
|
Week 49 up to Week 72
|
|
Number of Participants With Treatment Discontinuation Due to Futility
Tidsramme: Up to Week 48
|
Treatment discontinuation due to futility is defined as HCV RNA drop <3 log10 at Week 8, HCV RNA >/=100 IU/mL at Week 12, or HCV RNA >/=15 IU/mL at Week 24.
|
Up to Week 48
|
|
Number of Participants With Treatment Discontinuation
Tidsramme: Up to Week 48
|
Treatment discontinuation is reported by sub-categories of reasons for treatment discontinuation.
Futility rule is defined as HCV RNA drop <3 log10 at Week 8, HCV RNA >/=100 IU/mL at Week 12, or HCV RNA >/=15 IU/mL at Week 24.
|
Up to Week 48
|
|
Number of Participants With Adverse Events
Tidsramme: Up to 72 weeks
|
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Preexisting conditions which worsen during a study are also considered as adverse events.
|
Up to 72 weeks
|
|
Percentage of Participants With Positive Predictive Value of Participant Demographics for SVR Rate
Tidsramme: Screening (before Week 1)
|
Demographic characteristics recorded were age and gender.
Predictive value of these characteristics for SVR rate was to be assessed.
|
Screening (before Week 1)
|
|
Percentage of Participants With Positive Predictive Value of Liver Fibrosis
Tidsramme: Screening (before Week 1)
|
The following sub-categories of liver fibrosis were determined in this study: 1) no cirrhosis, 2) bridging fibrosis and 3) cirrhosis.
Predictive value of these sub-categories of liver fibrosis for SVR rate was to be assessed.
|
Screening (before Week 1)
|
|
Predictive Value of HCV Disease Characteristics
Tidsramme: Screening (before Week 1)
|
HCV disease characteristics evaluated were HCV genotype (subtype), including HCV 1(a) and HCV 1(b).
Predictive value of these disease characteristics for SVR rate were to be assessed.
|
Screening (before Week 1)
|
|
Percentage of Participants With Positive Predictive Value of Previous Virological Response (Null-response, Partial Response, or Relapse)
Tidsramme: Up to 72 weeks
|
Previous virological response was sub-categorized into the following categories: null-response, partial response, or relapse.
Predictive value of these sub-categories for SVR rate were to be assessed.
|
Up to 72 weeks
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. mai 2014
Primær fullføring (Faktiske)
1. mai 2015
Studiet fullført (Faktiske)
1. mai 2015
Datoer for studieregistrering
Først innsendt
16. april 2014
Først innsendt som oppfylte QC-kriteriene
16. april 2014
Først lagt ut (Anslag)
21. april 2014
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
12. desember 2016
Siste oppdatering sendt inn som oppfylte QC-kriteriene
18. oktober 2016
Sist bekreftet
1. oktober 2016
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- RNA-virusinfeksjoner
- Virussykdommer
- Infeksjoner
- Blodbårne infeksjoner
- Smittsomme sykdommer
- Leversykdommer
- Flaviviridae-infeksjoner
- Hepatitt, viral, menneskelig
- Enterovirusinfeksjoner
- Picornaviridae-infeksjoner
- Hepatitt, kronisk
- Hepatitt
- Hepatitt A-virus
- Hepatitt C
- Hepatitt C, kronisk
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Enzymhemmere
- Antimetabolitter
- Antineoplastiske midler
- Proteasehemmere
- Interferoner
- Ribavirin
- Simeprevir
Andre studie-ID-numre
- ML29278
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .